Purple Biotech Ltd.

Regulatory Filings • Sep 1, 2024

Purple Biotech to Participate at H.C. Wainwright 26th Annual Global Investment Conference

REHOVOT, Israel, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQTASE: PPBT), a clinical-stage company developing frst-in-class that overcome tumor immune evasion and drug resistance, today announced its executive management will participate in the H.C. Wainwight 26th Annual Global Investment a Fireside Chat presentation (virtual) and one-on-one meetings.

The conference is being held on September 9-11, 2024, and the virtual Fireside Chat will be available on-demand starting on Monday September 9 at 7:00 AM ET on the Investor of Purple Biotech's website at www.purple-biotech.com for 30 days. Institutional investors interested in listening to Purple Biotech's Fireside Chat may click on the following link (www.hcwevents.com/annualconference) to register for the conference.

Purple Biotech's CEO, Gil Efron, will also conduct in person one meetings with institutional investors in person venue at the Lotte New York Palace Hotel in New York City.

About Purple Biotech

Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage company developing first-in-class therapies tumor immune evasion and drug resistance. The Company's oncology pipeline includes CM24, NT219 is a humanized monoclonal antibody that blocks CEACAM1, that supports tumor immune evasion and survival through multiple pathways. CEACAM1 on tumor cells and neutrophils extracellular traps is a novel target for the treatment of multiple cancer indications. As a prof of concept of these novel pathways, the Company is advancing CM24 as a combination therapy with anti-PD-1 checkpoint inhibitors in a Phase 2 study for the treatment of pancreatic ductal adencarcinoma (PDAC). The Company has entered into a clinical collaboration agreement with Bristol Myers Squibb for the Phase 2 dinical trials to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. NT219 is a dual inhibitor, novel small molecule that simultaneously targets IRS1/2 and STAT3. A Phase 1 dose escalation study was concluded as a monotherapy and in which NT219 demonstrated anti-tumor activity in combination with cetuximab in second line patient and or metastatic SCCHN (RN SCCHN). The Company is advancing CAPTN-3, a precinical platform of conditionally-activated tri-specific antibody that engages both T cells and NK cells to induce a strong, localized immune response within the turner t. The cleavable capping technology confines the compound's therapeutic activity to the local tumor microenvironment, and there managed therapeutic window in patients. The third arm specifically targets the Tumor Associated Antigen (TAA). The technology presents a novel mechanism of action by unleashing both innate and adaptive immune systems to mount anti-tumoral immune response. IM1240 is the first tri-specific antibody in development that targets 574 expressed in a variety of solid turned disease, increased invasiveness and por clinical outcomes. The Company's corporate headquarters are located in Rehovot, Israel. For more information, please visit https://purplebiotech.com/

Forward-Looking Statements and Safe Harbor Statement

Certain statements in this press release that are forward-looking and not are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements of historical fact, and may be identified by words such as "believe", "expect", "intend", "plan", "may", "should", "might", "seek", "target", "torecas", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relates. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievemently different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the plans, strategies of management for future operations; product development for NT219, CM24 and IM1240; the process by which such early stage therapeutic candidates could potentially lead to an approved drug product is long and subject to highly significant risks, particularly with respect to a joint development collaboration; the fact that drug development and commercialization involves a lengthy process with uncertain outcomes; our ability to successfully develop and commercialize our pharmaceutical products, the expense, length, progress and results of any changes in regulation and legislation that could affect the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceuical products; the regulatory environment and changes in the countries in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents obtained by competitions; of our patents and other protections for innovative products; our ability to obtain and defend issued patents; the commencement of any patent interference or infingement action against our patents, and our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2023 and in our other filings with the U.S. Securities and Exchange Commission ("SEC"), including our cautionary discussion of risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date. We disclaim any intention or obligation to publicly update or revise any forward-looking statement or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC's website, https://www.sec.gov.

CONTACTS:

Company Contact:

Lior Fhima Chief Financial Officer IR@purple-biotech.com